Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA internal medicine"
DOI: 10.1001/jamainternmed.2021.5983
Abstract: Importance Launch prices of new cancer drugs in the US have substantially increased in recent years despite growing concerns about the quantity and quality of evidence supporting their approval by the US Food and Drug… read more here.
Keywords: cancer drugs; 2011 2018; targeted cancer; cancer ... See more keywords
Cost of care for patients with metastatic castration-resistant prostate cancer initiating on docetaxel versus oral targeted therapies in the United States.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.30_suppl.88
Abstract: 88 Background: Abiraterone acetate + prednisone and enzalutamide are approved oral targeted therapies (OTT) for metastatic castration-resistant prostate cancer (mCRPC) which have significant clinical benefit. However, their impact on healthcare cost relative to docetaxel (DOC)… read more here.
Keywords: doc; prostate cancer; cancer; cost ... See more keywords
QTc prolongation risk among patients receiving oral targeted antineoplastic medications: A real-world community-based oncology analysis
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1098333
Abstract: Introduction Thirty oral targeted antineoplastic agents are associated with prolongation of the QT interval. However, limited data exists regarding QTc prolongation and associated risk factors in the ambulatory oncology setting. Methods This retrospective study was… read more here.
Keywords: oncology; prolongation; qtc prolongation; risk ... See more keywords
Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14112493
Abstract: (1) Background: Oral targeted anticancer drugs are victims of presystemic pharmacokinetic drug–drug interactions (DDI). Identification of the nature of these DDIs, i.e., enzyme-based or/and transporter-based, is challenging, since most of these drugs are substrates of… read more here.
Keywords: anticancer drugs; methodology; targeted anticancer; drug ... See more keywords